Introduction {#sec1}
============

Hemangiopericytomas are rare vascular neoplasms related to smooth muscle perivascular cells known as pericytes. Initially described by its histopathologic, albeit nonspecific, staghorn vascular pattern, the diagnosis included several unrelated benign and malignant entities. With the advent of immunohistochemistry, histologic mimics were excluded and hemangiopericytoma became a distinct entity, although largely a diagnosis of exclusion. Grading is based on the Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) system that accounts for tumor differentiation, necrosis, and mitotic activity. Modern reports of extrauterine pelvic hemangiopericytomas are extremely rare. We report a case of a male patient who presented with obstructive urinary symptoms and hydronephrosis due to a pelvic hemangiopericytoma. We also summarize published reports of extrauterine pelvic hemangiopericytomas to date to raise awareness regarding the diversity of symptoms and diagnostic findings associated with this disease.

Case report {#sec2}
===========

A 55-year-old African American male with history of hypertension was referred for lower urinary tract symptoms (LUTS), new-onset left hydronephrosis and worsening renal function. His estimated glomerular filtration rate (eGFR) worsened from 84 mL/min to 52 mL/min within one year. At initial presentation, he reported nocturia, weak stream, severe urgency, and urge incontinence. Surgical history included take down of a left lower quadrant temporary colostomy that was initially created after emergent surgery for an abdominal gunshot wound 20 years ago. He reported being an active smoker and maternal history of kidney cancer. Initial renal ultrasound ordered by his primary care provider reported left hydroureteronephrosis and possibly an "enlarged prostate". Prostate-specific antigen measured 1.16 ng/mL. Uroflowmetry showed Qmax of 16.9 mL/sec and postvoid residual of 293 mL. Cystoscopy revealed distorted bladder lumen anatomy without a discernible interureteric ridge, and the left lateral wall showing evidence of extraluminal compression. The left ureteral orifice could not be identified.

CT imaging showed a centrally necrotic 9.3 cm × 9.7 cm × 10.3 cm pelvic mass posterior to the urinary bladder and superior to the prostate exerting a mass effect, and compressing the left ureter with resultant severe hydroureteronephrosis with cortical thinning ([Fig. 1](#fig1){ref-type="fig"}A and B). No radiologic evidence of metastatic disease was seen in the chest, abdomen or pelvis. Percutaneous biopsy of the mass showed rare atypical spindle cells that were immunoreactive for CD34, FLI-1 and CD99, suggesting an epithelioid mesenchymal neoplasm. A left nephrostomy tube was placed to salvage renal function. MRI demonstrated a necrotic pelvic mass displacing the bladder to the right and abutting the left seminal vesicle ([Fig. 1](#fig1){ref-type="fig"}C and D).Fig. 1Excretory phase computed tomography showed (**A**) a centrally necrotic pelvic mass displacing a contrast-filled urinary bladder to the right and (**B**) resulting in severe left hydroureteronephrosis with cortical thinning. (**C**) Coronal and (**D**) sagittal views on magnetic resonance imaging confirmed presence of a pelvic mass anterior to the rectum and displacing the urinary bladder.Fig. 1

The patient underwent open laparotomy for mass resection under general anesthesia. In supine position, a lower midline incision was made and the retropubic space was entered. Ureters were identified bilaterally and mobilized to the pelvis. The peritoneum was incised and the mass was mobilized off the bladder; it was not adherent to or invading the bladder. The right ureter was traced up to its insertion into the bladder. However, the distal left ureter was densely adherent to the mass; it was therefore divided proximally and removed with the mass *en bloc*. The left ureter was then extravesically reimplanted to the bladder dome in a tension-free manner. The mass did not appear to involve or invade any other pelvic structures. Bilateral ureteral stents were placed. A urethral catheter was placed in the bladder, and a Blake drain was placed in the retropubic space. Operative time was 365 mins with estimated blood loss of 600 mL. Patient had slow return of bowel function but otherwise uneventful hospital course and was discharged on post-operative day (POD) 4 after removal of the nephrostomy tube. Urethral catheter and Blake drain were removed after cystogram confirmed no contrast extravasation on POD 18; ureteral stents were removed on POD 32. He reported significant improvement of LUTS after recovering from surgery.

Gross evaluation of the 490 gm specimen revealed a well-circumscribed fleshy mass with a central necrotic lesion ([Fig. 2](#fig2){ref-type="fig"}). Final histopathological diagnosis was malignant hemangiopericytoma, FNCLCC grade 2. Specimen showed immunoreactivity for vimentin and CD34, with 15% cells being Ki67-positive. Repeat imaging at four months showed improvement of left hydroureteronephrosis with eGFR of 64 mL/min. The patient remains on surveillance with serial CT imaging of the chest, abdomen and pelvis every 3--4 months. He remains disease-free at 23 months of post-operative follow-up. No adjuvant chemotherapy or radiation has been administered.Fig. 2(**A**) Grossly, the 10.5 cm pelvic mass appeared well-circumscribed with a smooth surface. (**B**) Sectioning revealed a fleshy mass with a central necrotic lesion.Fig. 2

Discussion {#sec3}
==========

Solitary fibrous tumors comprise a histologic spectrum of mesenchymal neoplasms that are found in many locations, but are most commonly seen in the pleura, peritoneum, meninges and lower extremities.[@bib1] Hemangiopericytoma, a rare subset of malignant solitary fibrous tumors, are soft-tissue sarcomas that originate from mesenchymal cells with pericytic differentiation. Pericytes are arranged around capillaries and postcapillary venules; consequently, hemangiopericytomas may occur anywhere capillaries are found. These are usually slow-growing and painless. Extrauterine pelvic hemangiopericytomas are extremely rare; our literature review suggests that common presenting symptoms include vague abdominopelvic pain and those associated with mass effect ([Table 1](#tbl1){ref-type="table"}).Table 1Published reports of extrauterine pelvic hemangiopericytomas.Table 1Age (years)/SexSymptomsSize (cm)Location/Primary Treatment,\
Any Salvage TreatmentFollow-up (months)/Last Clinical StatusReport/Year/PMID56 MMass4Adherent to rectum^1^N/ABacon et al., 1950 ([15429830](https://pubmed.ncbi.nlm.nih.gov/15429830){#intref0010})34 FRectal bleed3.5 × 2.5Sigmoid, mesenteric border^1,5^60^b^Ault et al., 1951 ([14866696](https://pubmed.ncbi.nlm.nih.gov/14866696){#intref0015})40 FPain5Cul de sac^1,5^11^b^Forman et al., 1952 ([14914815](https://pubmed.ncbi.nlm.nih.gov/14914815){#intref0020})43 MMass20 × 11 × 10.5Pelvis^1,5,6^78^c^Wise et al., 1952 ([14932614](https://pubmed.ncbi.nlm.nih.gov/14932614){#intref0025})47 FPain8.5 × 7.8 × 6.7Left pelvis^1,6^N/AStout et al., 1956 ([13296384](https://pubmed.ncbi.nlm.nih.gov/13296384){#intref0030})11 MMassN/ALeft iliac fossa^2^119^c^Stout et al., 1956 ([13296384](https://pubmed.ncbi.nlm.nih.gov/13296384){#intref0035})50 FMass4.5 × 3 × 3.5Adherent to rectum^1^18^a^Slattery et al., 1956 ([13313911](https://pubmed.ncbi.nlm.nih.gov/13313911){#intref0040})16 FHypoglycemiaN/ALeft pelvis^1^11^c^Howard et al., 1959 ([13630072](https://pubmed.ncbi.nlm.nih.gov/13630072){#intref0045})50 FN/A4.5Adherent to rectum^1^48^a^Fisher et al., 1960 ([13699977](https://pubmed.ncbi.nlm.nih.gov/13699977){#intref0050})39 FPain15 × 10 × 10Retroperitoneal^1,5^39^a^Spiro et al., 1964 ([14207337](https://pubmed.ncbi.nlm.nih.gov/14207337){#intref0055})73 FNone25 × 15 × 10Retroperitoneal^4^96^a^Wilbanks et al., 1975 ([1200042](https://pubmed.ncbi.nlm.nih.gov/1200042){#intref0060})58 MBladder outlet obstructionN/APelvis^1^N/A^a^Roberts et al., 1977 ([883072](https://pubmed.ncbi.nlm.nih.gov/883072){#intref0065})29 FDyspareunia, dysuriaN/ARetroperitoneal^1^N/AKaude et al., 1980 ([6448795](https://pubmed.ncbi.nlm.nih.gov/6448795){#intref0070})57 MPain8Pelvis^1^N/AYoo et al., 1986 ([3943360](https://pubmed.ncbi.nlm.nih.gov/3943360){#intref0075})59 FPain15 × 15Pelvis^2,6^24^a^Kehagias et al., 1999 ([9933402](https://pubmed.ncbi.nlm.nih.gov/9933402){#intref0080})40 MNone14 × 9Pelvis^1^N/ARosenblatt et al., 2001 ([11586234](https://pubmed.ncbi.nlm.nih.gov/11586234){#intref0085})19 MPain7 × 6 × 9Right pelvic wall^3,5^88^a^Unal et al., 2002 ([11816000](https://pubmed.ncbi.nlm.nih.gov/11816000){#intref0090})42 FPain7 × 7 × 5Inguinal^3,5^64^a^Unal et al., 2002 ([11816000](https://pubmed.ncbi.nlm.nih.gov/11816000){#intref0095})34 MPain, mass10 × 12 × 10Pelvic wall^3,5^13^a^Unal et al., 2002 ([11816000](https://pubmed.ncbi.nlm.nih.gov/11816000){#intref0100})58 FPain, constipation, frequencyN/ARight ischiorectal fossa, ischiopubic ramus^2^12^a^Perdikakis et al., 2011 ([22933930](https://pubmed.ncbi.nlm.nih.gov/22933930){#intref0105})63 FPain12 × 9 × 9.4Pouch of Douglas^1^N/A^a^Álvarez Abad et al., 2017 ([26912344](https://pubmed.ncbi.nlm.nih.gov/26912344/){#intref0110})55 MBladder outlet obstruction9.3 × 9.7 × 10.3Pelvis^1^23^a^Mitra et al., 2020 (Present study)[^1][^2][^3][^4][^5][^6][^7][^8][^9][^10]

Hemangiopericytomas appear to be equally distributed among genders and age groups. Imaging is usually non-specific and may show a homogenous mass surrounded by a capsule with vascular enhancement. Immunohistochemical findings include reactivity for CD34, CD99 and vimentin.[@bib2]^,^[@bib3] Clinical behavior may range from a benign course to malignant transformation. Since most hemangiopericytomas are not metastatic at presentation, surgery remains the gold standard treatment and is associated with high disease-free survival rates.[@bib4] However, the unpredictable tumor behavior necessitates close follow-up and adjuvant therapy for aggressive disease. Adjuvant radiation may confer a survival benefit, especially in patients with high-grade disease.[@bib5]

Conclusion {#sec4}
==========

Extrauterine pelvic hemangiopericytomas presenting with LUTS and obstruction are extremely rare in the urologic setting. As in this case, while clinical diagnosis may not be immediately apparent, oncologic surgical principles regarding mass excision should be strictly followed for optimal outcomes. In conclusion, although rare, hemangiopericytomas should remain on a clinician\'s differential diagnosis when a patient presents with abdominopelvic pain due to an extrauterine pelvic mass and symptoms associated with compression of surrounding structures. Even if the mass appears radiographically benign and biopsy suggests an epithelioid mesenchymal neoplasm, it should be aggressively resected given the potential for malignant transformation, and the patient must be followed closely to evaluate for recurrence and metastasis.
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[^1]: ***Abbreviations***: F, female; M, male; N/A, not available; PMID, PubMed identifier, available at [pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov){#intref0015a}.

[^2]: ^1^Surgical resection.

[^3]: ^2^Radiotherapy.

[^4]: ^3^Hyperthermic pelvic chemotherapy perfusion.

[^5]: ^4^N/A.

[^6]: ^5^Salvage resection.

[^7]: ^6^Adjuvant or salvage radiotherapy.

[^8]: ^a^Alive with no evidence of disease.

[^9]: ^b^Alive with disease.

[^10]: ^c^Dead of disease.
